Efficacy and safety of fludarabine/cyclophosphamide (FC) as front-line treatment of CLL. Final results of a phase II clinical trial in a single center.

被引：0
|
作者：
Marin-Niebla, A [1 ]
Rios-Herranz, E [1 ]
Rodriguez, JM [1 ]
Nunez, R [1 ]
Herrera, A [1 ]
Parody, R [1 ]
Espigado, I [1 ]
机构：
[1] Hosp Virgen Rocio, Seville, Spain
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.4826.4826
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4826
引用
收藏
页码：289B / 289B
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer
    Gonzalez-Martin, Antonio
    Gladieff, Laurence
    Tholander, Bengt
    Stroyakovsky, Daniel
    Gore, Martin
    Scambia, Giovanni
    Kovalenko, Nadezhda
    Oaknin, Ana
    Ronco, Julian Perez
    Freudensprung, Ulrich
    Pignata, Sandro
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (18) : 3831 - 3838
  • [12] Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL):: Results of two phase II studies (CLL2-protocol) of the german cll study group (GCLLSG).
    Hallek, M
    Wilhelm, M
    Emmerich, B
    Döhner, H
    Fostitsch, HP
    Sezer, O
    Herold, M
    Knauf, W
    Busch, R
    Schmitt, B
    Wendtner, CM
    Kuse, R
    Freund, M
    Franke, A
    Schriever, F
    Nerl, C
    Thiel, E
    Hiddemann, W
    Brittinger, G
    BLOOD, 1999, 94 (10) : 313A - 313A
  • [13] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Montserrat, Emili
    BLOOD, 2011, 118 (21) : 136 - 137
  • [14] Rituximab (R) in combination with fludarabine (F) and cyclophosphamide (C) in relapsed follicular lymphoma (FL) patients (pts). Final results of FC plus R phase II trial by the GISL.
    Sacchi, Stefano
    Pozzi, Samantha
    Marcheselli, Raffaella
    Luminari, Stefano
    Federico, Massimo
    Tucci, Alessandra
    Merli, Francesco
    Orsucci, Loretta
    Cervetti, Giulia
    Occhini, Ubaldo
    Liberati, Marina
    Callea, Vincenzo
    Brugiatelli, Maura
    Baldini, Luca
    BLOOD, 2006, 108 (11) : 782A - 782A
  • [15] Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study
    Siefker-Radtke, Arlene O.
    Campbell, Matthew T.
    Munsell, Mark F.
    Harris, Deborah R.
    Carolla, Robert L.
    Pagliaro, Lance C.
    UROLOGY, 2016, 89 : 83 - 89
  • [16] Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC plus G) Versus Chlorambucil Plus Obinutuzumab (Cbl plus G) As Front-Line Therapy
    Mulligan, Stephen P.
    Freeman, Jane A.
    Badoux, Xavier
    Eek, Richard
    Cull, Gavin
    Mackinlay, Naomi J.
    Murphy, Nicholas E.
    Carradice, Duncan P.
    Solterbeck, Ann C.
    Best, Oliver Giles
    Tam, Constantine S.
    Kuss, Bryone J.
    BLOOD, 2018, 132
  • [17] Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
    Ma, Shoucheng
    Chen, Rui
    Duan, Ling
    Li, Chunmei
    Yang, Tianning
    Wang, Jiankai
    Zhao, Da
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (02) : 1052 - 1063
  • [18] FRONT-LINE THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE, OFATUMUMAB (FC-O2) IN YOUNG (≤ 65 YRS) AND FIT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. RESULTS OF THE PROSPECTIVE PHASE 2 GIMEMA STUDY LLC0911
    Mauro, F. R.
    Molica, S.
    Zaja, F.
    Piciocchi, A.
    Ilariucci, F.
    Coscia, M.
    Carella, A. M.
    Re, F.
    Liberati, A. M.
    Tedeschi, A.
    Gozzetti, A.
    Cuneo, A.
    Cortelezzi, A.
    Baraldi, A.
    Del Poeta, G.
    Musolino, C.
    Battistini, R.
    De Propris, M. S.
    Della Starza, I.
    Raponi, S.
    Ilari, C.
    Cafforio, L.
    Nanni, M.
    Fazi, P.
    Vignetti, M.
    Russo, F.
    Porrazzo, M.
    Riemma, C.
    Specchia, G.
    Neri, A.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 6 - 6
  • [19] Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial
    Padron, Eric
    Tinsley-Vance, Sara M.
    DeZern, Amy E.
    Carraway, Hetty E.
    Luskin, Marlise R.
    Roboz, Gail J.
    Chan, Onyee
    Horton, Meagan
    Gerds, Aaron T.
    Sallman, David A.
    Kuykendall, Andrew
    Steensma, David
    Balasis, Maria E.
    Lancet, Jeffrey E.
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    BLOOD, 2022, 140 : 1101 - 1103
  • [20] Efficacy and Safety of Zoledronic Acid Plus Sorafenib for Advanced Hepatocellular Carcinoma Patients: A Single Center, Single Arm, Phase II Clinical Trial
    Zhang, Lan
    Xie, Xiaoying
    Ren, Zheng Gang
    Sun, Hui Chuan
    HEPATOLOGY, 2018, 68 : 216A - 216A
12345